Literature DB >> 26117983

Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics - our experience.

Marcin Michalak, Emilia Gąsiorowska, Ewa Nowak Markwitz.   

Abstract

OBJECTIVES: The aim of this study was to compare and evaluate the quality of CA 125, HE4, logistic regression model based on CA 125 and HE4, and ROMA algorithm in preoperational differential diagnostics of the ovarian tumors.
MATERIAL AND METHODS: To the study 110 patients enrolled. Based on histopatological examination of removed tumors, they were divided into study group (56 cancer patients) and control one (nonmalignant 54 patients). Serum CA 125 and HE4 concentrations were measured following a standard procedure.
RESULTS: A commonly accepted referential value for CA 125 is 35 IU/ml. In our study this cut-off value yielded very low sensitivity and specificity results (85.2% and 63.6%, respectively). When we adopted HE4 normal value to be 140 pM,the sensitivity and specificity obtained in the investigated population was 68.5% and 94.6%, respectively When the cut-off value for HE4 was adopted as 74 pM, the sensitivity improved considerably (88.9%), but specificity decreased to 85.7%. In case of CA 125 when we adopted Ca 125 normal value to be 77 IU/ml, the sensitivity and specificity obtained in the investigated population was 81.5% and 83.6%, respectively In analysis based on combination of biomarkers, the highest sensitivity was obtained for the logistic regression model based on CA 125 and HE4 (89.5%). A little bit lower sensitivity was achieved for HE4 used as a single diagnostic test (88.9%). The highest specificity was observed for ROMA algorithm (94.5%). This means that ROMA algorithm is the best diagnostic tool to differentiate between the malignant and non-malignant ovarian tumors.
CONCLUSIONS: 1. ROMA algorithm yielded the highest specificity and slightly lower sensitivity in the case of differential diagnosis between malignant and non-malignant ovarian tumors. Therefore, it should become a basic tool in the ovarian tumors diagnosis prior to a surgery 2. HE4 as a single diagnostic test (based on one marker) was found to be better suited to the ovarian tumor differential diagnosis than CA 125 test. 3. Combined test, based on double marker analysis, should be applied and then the risk of the ovarian cancer should be calculated. This approach is more effective than single marker analysis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26117983     DOI: 10.17772/gp/2070

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  5 in total

1.  Accuracy of Pelvic Mass Score in Pre-operative Determination of Malignancy in Adnexal Masses.

Authors:  Lakshmi Mohan; Arun Rao; Sonali Ullal; Gowtham Krishna
Journal:  J Clin Diagn Res       Date:  2016-11-01

2.  The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses.

Authors:  Zehra Nihal Dolgun; Canan Kabaca; Ateş Karateke; Cem İyibozkurt; Cihan İnan; Ahmet Salih Altıntaş; Cihan Karadağ
Journal:  Balkan Med J       Date:  2017-04-05       Impact factor: 2.021

3.  Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.

Authors:  Felix Leung; Marcus Q Bernardini; Marshall D Brown; Yingye Zheng; Rafael Molina; Robert C Bast; Gerard Davis; Stefano Serra; Eleftherios P Diamandis; Vathany Kulasingam
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-07-22       Impact factor: 4.254

4.  Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer.

Authors:  Josef Chovanec; Iveta Selingerova; Kristina Greplova; Sofie Leisby Antonsen; Monika Nalezinska; Claus Høgdall; Estrid Høgdall; Erik Søgaard-Andersen; Kirsten M Jochumsen; Pavel Fabian; Dalibor Valik; Lenka Zdrazilova-Dubska
Journal:  Oncotarget       Date:  2017-11-21

5.  Analysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer.

Authors:  Nabil Abdalla; Robert Piorkowski; Anna Slomka; Malgorzata Kania; Wlodzimierz Sawicki; Krzysztof Cendrowski
Journal:  Contemp Oncol (Pozn)       Date:  2017-01-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.